NCT02225821

Brief Summary

In the Netherlands about 18,000 surgical procedures with implant removal are annually performed after fracture healing, of which 30-80% concern the foot, ankle and lower leg region. For clean surgical procedures, the rate of postoperative wound infections (POWIs) should be less than 5%. However, rates of 10-12% following implant removal, specifically after foot, ankle and lower leg fractures are reported. Currently, surgeons decide individually if antibiotics prophylaxis is given, since no guideline exists. This leads to undesirable practice variation. Therefore, the investigators propose a double-blind randomized controlled trial (RCT) in patients scheduled for implant removal following a foot, ankle or lower leg fracture, to assess the (cost-)effectiveness of a single gift of antibiotic prophylaxis. Primary outcome is a POWI within 30 days after implant removal. Secondary outcomes are quality of life, functional outcome at 30 days and 6 months after implant removal and costs. With 2 x 250 patients a decrease in POWI from 10% to 3.3% (expected rate in clean-contaminated elective orthopedic trauma procedures) can be detected (Power=80%, 2-sided alpha=5%, including 15% lost to follow up). If the assumption of the investigators, that prophylactic antibiotics prior to implant removal reduces the infectious complication rate, is confirmed by this RCT, this will offer a strong argument to adopt a single gift of antibiotic prophylaxis as standard practice of care. This will reduce the incidence of POWIs and consequently will lead to less physical and social disabilities and health care use. In addition, it will decrease the rate of use of empiric broad-spectrum antibiotics (and antibiotic resistance) prescribed upon suspicion or diagnosis of a POWI. A preliminary, conservative estimation suggests yearly cost savings in the Netherlands of €3.5 million per year.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Nov 2014

Geographic Reach
1 country

21 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 25, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 26, 2014

Completed
2 months until next milestone

Study Start

First participant enrolled

November 1, 2014

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2016

Completed
Last Updated

December 22, 2016

Status Verified

December 1, 2016

Enrollment Period

2 years

First QC Date

August 25, 2014

Last Update Submit

December 21, 2016

Conditions

Keywords

Implant RemovalAntibiotic ProphylaxisPostoperative wound infectionOrthopedics

Outcome Measures

Primary Outcomes (1)

  • Postoperative wound infection (POWI)

    The primary outcome variable is a POWI within 30 days after implant removal as defined by the criteria applied by the Centers for Disease and Control.

    30 days

Secondary Outcomes (4)

  • Health-related quality of life

    baseline, one month, 6 months

  • Functional outcome

    baseline, 1 month, 6 months

  • Patient satisfaction

    1 month, 6 months

  • Health care resources utilization

    baseline, 1 month, 6 months

Other Outcomes (1)

  • Costs

    Costs per quality adjusted life year

Study Arms (2)

antibiotic prophylaxis

ACTIVE COMPARATOR

a single gift of 1000 mg cefazolin in 10 cc of NaCl 0.9% (intervention group)

Drug: Cephalozin

No antibiotic prophylaxis

PLACEBO COMPARATOR

a single gift of 10 cc NaCl 0.9%, given in the same manner (control group).

Other: Sodium chloride

Interventions

1000 mg Cephalozin

Also known as: Kefzol
antibiotic prophylaxis

10 cc of NaCl 0.9%

Also known as: NaCl 0.9%
No antibiotic prophylaxis

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients ≥18 years and ≤75 years of all ethnic backgrounds
  • Implant removal following foot, ankle and/or lower leg surgery

You may not qualify if:

  • Removing and re-implanting osteosynthesis material in the same session
  • Active wound infection or (plate) fistula
  • Antibiotic treatment at time of elective implant removal for a concomitant disease or infection
  • A medical history of an allergic reaction to a cephalosporin, penicillin, or any other β-lactam antibiotic.
  • Insufficient comprehension of the Dutch language to understand the patient information to make an informed decision to participate.
  • Kidney disease (eGFR \<60 ml/min/1.73m\^2).
  • Treatment with probenecide, anticoagulants (see SPC)
  • Pregnancy and lactation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (21)

Medisch Centrum Alkmaar

Alkmaar, Netherlands

Location

Flevoziekenhuis

Almere Stad, Netherlands

Location

Amstelland Ziekenhuis

Amstelveen, Netherlands

Location

Academic Medical Center

Amsterdam, Netherlands

Location

BovenIJ Ziekenhuis

Amsterdam, Netherlands

Location

Onze Lieve Vrouwe Gasthuis

Amsterdam, Netherlands

Location

Sint Lucas Andreas Ziekenhuis

Amsterdam, Netherlands

Location

VU Medisch Centrum

Amsterdam, Netherlands

Location

Gelre Ziekenhuizen

Apeldoorn, Netherlands

Location

Rode Kruis Ziekenhuis

Beverwijk, Netherlands

Location

Amphia Ziekenhuis

Breda, Netherlands

Location

Reinier de Graaf

Delft, Netherlands

Location

Deventer Ziekenhuis

Deventer, Netherlands

Location

Catharina Ziekenhuis

Eindhoven, Netherlands

Location

Elkerliek Ziekenhuis

Helmond, Netherlands

Location

Tergooiziekenhuizen

Hilversum, Netherlands

Location

Spaarne Ziekenhuis

Hoofddorp, Netherlands

Location

Westfries Gasthuis

Hoorn, Netherlands

Location

Rijnland Ziekenhuis

Leiderdorp, Netherlands

Location

Vlietland Ziekenhuis

Schiedam, Netherlands

Location

MC Haaglanden

The Hague, Netherlands

Location

Related Publications (3)

  • Backes M, Schep NW, Luitse JS, Goslings JC, Schepers T. Indications for implant removal following intra-articular calcaneal fractures and subsequent complications. Foot Ankle Int. 2013 Nov;34(11):1521-5. doi: 10.1177/1071100713502466. Epub 2013 Sep 13.

    PMID: 24038057BACKGROUND
  • Backes M, Dingemans SA, Schep NW, Bloemers FW, Van Dijkman B, Garssen FP, Haverlag R, Hoogendoorn JM, Joosse P, Mirck B, Postma V, Ritchie E, Roerdink WH, Sintenie JB, Soesman NM, Sosef NL, Twigt BA, Van Veen RN, Van der Veen AH, Van Velde R, Vos DI, De Vries MR, Winkelhagen J, Goslings JC, Schepers T. Wound Infections Following Implant removal below the knee: the effect of antibiotic prophylaxis; the WIFI-trial, a multi-centre randomized controlled trial. BMC Surg. 2015 Feb 6;15:12. doi: 10.1186/1471-2482-15-12.

    PMID: 25972101BACKGROUND
  • Backes M, Dingemans SA, Dijkgraaf MGW, van den Berg HR, van Dijkman B, Hoogendoorn JM, Joosse P, Ritchie ED, Roerdink WH, Schots JPM, Sosef NL, Spijkerman IJB, Twigt BA, van der Veen AH, van Veen RN, Vermeulen J, Vos DI, Winkelhagen J, Goslings JC, Schepers T; WIFI Collaboration Group. Effect of Antibiotic Prophylaxis on Surgical Site Infections Following Removal of Orthopedic Implants Used for Treatment of Foot, Ankle, and Lower Leg Fractures: A Randomized Clinical Trial. JAMA. 2017 Dec 26;318(24):2438-2445. doi: 10.1001/jama.2017.19343.

MeSH Terms

Conditions

Surgical Wound Infection

Interventions

CefazolinSodium Chloride

Condition Hierarchy (Ancestors)

Wound InfectionInfectionsPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cephalosporinsbeta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Manouk Backes, MD, MSc

    Academic Medical Center/Sint Lucas Andreas Hospital

    STUDY CHAIR
  • Tim Schepers, MD, PhD

    Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

August 25, 2014

First Posted

August 26, 2014

Study Start

November 1, 2014

Primary Completion

November 1, 2016

Study Completion

November 1, 2016

Last Updated

December 22, 2016

Record last verified: 2016-12

Locations